Clinical Research Directory
Browse clinical research sites, groups, and studies.
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Sponsor: Shirley Ryan AbilityLab
Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Official title: Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2025-02-01
Completion Date
2026-03
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
Dalfampridine
The study drug (4-AP) will be administered as a 10 mg dose twice a day.
Placebo
The placebo provided by the SRAL pharmacy that looks identical to the 4-AP, will be administered twice a day.
STDP stimulation
Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
Exercise training
Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
Locations (1)
Shirley Ryan Abilitylab
Chicago, Illinois, United States